Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 427

1.

A Clinical Trial of Isradipine: What Went Wrong?

Maiti B, Perlmutter JS.

Ann Intern Med. 2020 Mar 31. doi: 10.7326/M20-1023. [Epub ahead of print] No abstract available.

PMID:
32227234
2.

Defining research priorities in dystonia.

Lungu C, Ozelius L, Standaert D, Hallett M, Sieber BA, Swanson-Fisher C, Berman BD, Calakos N, Moore JC, Perlmutter JS, Pirio Richardson SE, Saunders-Pullman R, Scheinfeldt L, Sharma N, Sillitoe R, Simonyan K, Starr PA, Taylor A, Vitek J; participants and organizers of the NINDS Workshop on Research Priorities in Dystonia.

Neurology. 2020 Mar 24;94(12):526-537. doi: 10.1212/WNL.0000000000009140. Epub 2020 Feb 25. Review.

PMID:
32098856
3.

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.

Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ.

JAMA Oncol. 2020 Feb 13. doi: 10.1001/jamaoncol.2019.6650. [Epub ahead of print]

PMID:
32053137
4.

MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.

Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ; I-SPY 2 Consortium.

J Clin Oncol. 2020 Apr 1;38(10):1059-1069. doi: 10.1200/JCO.19.01027. Epub 2019 Feb 7.

PMID:
32031889
5.

APOE genotype regulates pathology and disease progression in synucleinopathy.

Davis AA, Inman CE, Wargel ZM, Dube U, Freeberg BM, Galluppi A, Haines JN, Dhavale DD, Miller R, Choudhury FA, Sullivan PM, Cruchaga C, Perlmutter JS, Ulrich JD, Benitez BA, Kotzbauer PT, Holtzman DM.

Sci Transl Med. 2020 Feb 5;12(529). pii: eaay3069. doi: 10.1126/scitranslmed.aay3069.

PMID:
32024799
6.

Postural Directionality and Head Tremor in Cervical Dystonia.

Chen Q, Vu JP, Cisneros E, Benadof CN, Zhang Z, Barbano RL, Goetz CG, Jankovic J, Jinnah HA, Perlmutter JS, Appelbaum MI, Stebbins GT, Comella CL, Peterson DA.

Tremor Other Hyperkinet Mov (N Y). 2020 Jan 20;10. doi: 10.7916/tohm.v0.745. eCollection 2020.

7.

Transgenic Testing Does Not Support a Role for Additional Candidate Genes in Wolbachia Male Killing or Cytoplasmic Incompatibility.

Perlmutter JI, Meyers JE, Bordenstein SR.

mSystems. 2020 Jan 14;5(1). pii: e00658-19. doi: 10.1128/mSystems.00658-19.

8.

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.

Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC.

J Clin Oncol. 2020 Jan 13:JCO1902309. doi: 10.1200/JCO.19.02309. [Epub ahead of print]

PMID:
31928404
9.

Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.

Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC.

Arch Pathol Lab Med. 2020 Jan 13. doi: 10.5858/arpa.2019-0904-SA. [Epub ahead of print]

PMID:
31928354
10.

Microorganisms in the reproductive tissues of arthropods.

Perlmutter JI, Bordenstein SR.

Nat Rev Microbiol. 2020 Feb;18(2):97-111. doi: 10.1038/s41579-019-0309-z. Epub 2020 Jan 6. Review.

PMID:
31907461
11.

Little Change in Functional Brain Networks Following Acute Levodopa in Drug-Naïve Parkinson's Disease.

White RL 3rd, Campbell MC, Yang D, Shannon W, Snyder AZ, Perlmutter JS.

Mov Disord. 2020 Mar;35(3):499-503. doi: 10.1002/mds.27942. Epub 2019 Dec 19.

PMID:
31854465
12.

Psychometric properties and responsiveness of Neuro-QoL Cognitive Function in persons with Huntington disease (HD).

Carlozzi NE, Boileau NR, Paulsen JS, Downing NR, Ready R, Perlmutter JS, Cella D, Chou KL, McCormack MK, Barton S, Lai JS.

Qual Life Res. 2019 Dec 18. doi: 10.1007/s11136-019-02391-7. [Epub ahead of print]

PMID:
31853881
13.

Proteinopathy and longitudinal changes in functional connectivity networks in Parkinson disease.

Campbell MC, Jackson JJ, Koller JM, Snyder AZ, Kotzbauer PT, Perlmutter JS.

Neurology. 2020 Feb 18;94(7):e718-e728. doi: 10.1212/WNL.0000000000008677. Epub 2019 Dec 18.

PMID:
31852813
14.

Cognitive correlates of cerebellar resting-state functional connectivity in Parkinson disease.

Maiti B, Koller JM, Snyder AZ, Tanenbaum AB, Norris SA, Campbell MC, Perlmutter JS.

Neurology. 2020 Jan 28;94(4):e384-e396. doi: 10.1212/WNL.0000000000008754. Epub 2019 Dec 17.

PMID:
31848257
15.

Risk of spread in adult-onset isolated focal dystonia: a prospective international cohort study.

Berman BD, Groth CL, Sillau SH, Pirio Richardson S, Norris SA, Junker J, Brüggemann N, Agarwal P, Barbano RL, Espay AJ, Vizcarra JA, Klein C, Bäumer T, Loens S, Reich SG, Vidailhet M, Bonnet C, Roze E, Jinnah HA, Perlmutter JS.

J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):314-320. doi: 10.1136/jnnp-2019-321794. Epub 2019 Dec 17.

16.

Striatal DAT SPECT: Caveat Emptor!

Perlmutter JS, Stoessl AJ.

Mov Disord. 2019 Oct;34(10):1430-1432. doi: 10.1002/mds.27811. No abstract available.

PMID:
31769089
17.

Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Yang P, Perlmutter JS, Benzinger TLS, Morris JC, Xu J.

Ageing Res Rev. 2020 Jan;57:100994. doi: 10.1016/j.arr.2019.100994. Epub 2019 Nov 22. Review.

18.

The impact of dopamine D2-like agonist/antagonist on [18F]VAT PET measurement of VAChT in the brain of nonhuman primates.

Liu H, Luo Z, Gu J, Su Y, Flores H, Parsons SM, Zhou Y, Perlmutter JS, Tu Z.

Eur J Pharm Sci. 2020 Feb 15;143:105152. doi: 10.1016/j.ejps.2019.105152. Epub 2019 Nov 15.

PMID:
31740395
19.

Paternal Grandmother Age Affects the Strength of Wolbachia-Induced Cytoplasmic Incompatibility in Drosophila melanogaster.

Layton EM, On J, Perlmutter JI, Bordenstein SR, Shropshire JD.

mBio. 2019 Nov 5;10(6). pii: e01879-19. doi: 10.1128/mBio.01879-19.

20.

Detecting associations between intact connectomes and clinical covariates using recursive partitioning object-oriented data analysis.

Yang D, Deych E, Shands B, Campbell MC, Perlmutter JS, Petersen S, Schlaggar BL, Shannon W.

Stat Med. 2019 Dec 20;38(29):5486-5496. doi: 10.1002/sim.8374. Epub 2019 Oct 25.

PMID:
31650580
21.

The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases.

Li H, Yang P, Knight W, Guo Y, Perlmutter JS, Benzinger TLS, Morris JC, Xu J.

J Neurochem. 2020 Jan;152(2):235-251. doi: 10.1111/jnc.14898. Epub 2019 Nov 4.

22.

How different aspects of motor dysfunction influence day-to-day function in huntington's disease.

Carlozzi NE, Schilling SG, Boileau NR, Chou KL, Perlmutter JS, Frank S, McCormack MK, Stout JC, Paulsen JS, Lai JS, Dayalu P.

Mov Disord. 2019 Dec;34(12):1910-1914. doi: 10.1002/mds.27866. Epub 2019 Oct 14.

PMID:
31609508
23.

The phage gene wmk is a candidate for male killing by a bacterial endosymbiont.

Perlmutter JI, Bordenstein SR, Unckless RL, LePage DP, Metcalf JA, Hill T, Martinez J, Jiggins FM, Bordenstein SR.

PLoS Pathog. 2019 Sep 10;15(9):e1007936. doi: 10.1371/journal.ppat.1007936. eCollection 2019 Sep.

24.

Neuroinflammation and Myelin Status in Alzheimer's Disease, Parkinson's Disease, and Normal Aging Brains: A Small Sample Study.

Han F, Perrin RJ, Wang Q, Wang Y, Perlmutter JS, Morris JC, Benzinger TLS, Xu J.

Parkinsons Dis. 2019 Jul 4;2019:7975407. doi: 10.1155/2019/7975407. eCollection 2019.

25.

Low Back Pain--Related Disability in Parkinson Disease: Impact on Functional Mobility, Physical Activity, and Quality of Life.

Duncan RP, Van Dillen LR, Garbutt JM, Earhart GM, Perlmutter JS.

Phys Ther. 2019 Oct 28;99(10):1346-1353. doi: 10.1093/ptj/pzz094.

PMID:
31343700
26.

Automated production of a sphingosine-1 phosphate receptor 1 (S1P1) PET radiopharmaceutical [11C]CS1P1 for human use.

Luo Z, Gu J, Dennett RC, Gaehle GG, Perlmutter JS, Chen DL, Benzinger TLS, Tu Z.

Appl Radiat Isot. 2019 Oct;152:30-36. doi: 10.1016/j.apradiso.2019.06.029. Epub 2019 Jun 20.

PMID:
31280104
27.

End-of-life measures in Huntington disease: HDQLIFE Meaning and Purpose, Concern with Death and Dying, and End of Life Planning.

Carlozzi NE, Boileau NR, Paulsen JS, Perlmutter JS, Lai JS, Hahn EA, McCormack MK, Nance MA, Cella D, Barton SK, Downing NR.

J Neurol. 2019 Oct;266(10):2406-2422. doi: 10.1007/s00415-019-09417-7. Epub 2019 Jun 12.

PMID:
31190171
28.

Development of a carbon-11 PET radiotracer for imaging TRPC5 in the brain.

Yu Y, Liang Q, Liu H, Luo Z, Hu H, Perlmutter JS, Tu Z.

Org Biomol Chem. 2019 Jun 5;17(22):5586-5594. doi: 10.1039/c9ob00893d.

PMID:
31115430
29.

Head tremor at disease onset: an ataxic phenotype of cervical dystonia.

Merola A, Dwivedi AK, Shaikh AG, Tareen TK, Da Prat GA, Kauffman MA, Hampf J, Mahajan A, Marsili L, Jankovic J, Comella CL, Berman BD, Perlmutter JS, Jinnah HA, Espay AJ.

J Neurol. 2019 Aug;266(8):1844-1851. doi: 10.1007/s00415-019-09341-w. Epub 2019 Apr 26.

PMID:
31028543
30.

Current Landscape of Immunotherapy in Breast Cancer: A Review.

Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EA.

JAMA Oncol. 2019 Apr 11. doi: 10.1001/jamaoncol.2018.7147. [Epub ahead of print]

PMID:
30973611
31.

Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ; I-SPY2 Investigators.

NPJ Breast Cancer. 2019 Jan 2;5:2. doi: 10.1038/s41523-018-0096-0. eCollection 2019.

32.

Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA, Stella PJ, Voest E, Yost KJ, Perlmutter J, Pinto N, Kim ES, Schilsky RL.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00122. Epub 2018 Jul 11.

33.

Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.

Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL.

J Natl Cancer Inst. 2019 Feb 1;111(2):118-128. doi: 10.1093/jnci/djy196. Review.

34.

Exercise and Parkinson Disease: Comparing Tango, Treadmill, and Stretching.

Rawson KS, McNeely ME, Duncan RP, Pickett KA, Perlmutter JS, Earhart GM.

J Neurol Phys Ther. 2019 Jan;43(1):26-32. doi: 10.1097/NPT.0000000000000245.

35.

Thalamic and ventricular volumes predict motor response to deep brain stimulation for Parkinson's disease.

Younce JR, Campbell MC, Perlmutter JS, Norris SA.

Parkinsonism Relat Disord. 2019 Apr;61:64-69. doi: 10.1016/j.parkreldis.2018.11.026. Epub 2018 Nov 28.

36.

Syntheses and in vitro biological evaluation of S1PR1 ligands and PET studies of four F-18 labeled radiotracers in the brain of nonhuman primates.

Luo Z, Han J, Liu H, Rosenberg AJ, Chen DL, Gropler RJ, Perlmutter JS, Tu Z.

Org Biomol Chem. 2018 Dec 5;16(47):9171-9184. doi: 10.1039/c8ob02609b.

37.

Emergent Functional Network Effects in Parkinson Disease.

Gratton C, Koller JM, Shannon W, Greene DJ, Maiti B, Snyder AZ, Petersen SE, Perlmutter JS, Campbell MC.

Cereb Cortex. 2019 Apr 1;29(4):1701. doi: 10.1093/cercor/bhy229. No abstract available.

PMID:
30418543
38.

Predictors of alcohol responsiveness in dystonia.

Junker J, Brandt V, Berman BD, Vidailhet M, Roze E, Weissbach A, Comella C, Malaty IA, Jankovic J, LeDoux MS, Berardelli A, Barbano R, Reich SG, Perlmutter JS, Jinnah HA, Brüggemann N.

Neurology. 2018 Nov 20;91(21):e2020-e2026. doi: 10.1212/WNL.0000000000006551. Epub 2018 Oct 19.

39.

PET Imaging in Movement Disorders.

Maiti B, Perlmutter JS.

Semin Nucl Med. 2018 Nov;48(6):513-524. doi: 10.1053/j.semnuclmed.2018.07.006. Epub 2018 Aug 16. Review.

40.

Radiosynthesis and evaluation of a fluorine-18 labeled radioligand targeting vesicular acetylcholine transporter.

Yue X, Luo Z, Liu H, Kaneshige K, Parsons SM, Perlmutter JS, Tu Z.

Bioorg Med Chem Lett. 2018 Nov 15;28(21):3425-3430. doi: 10.1016/j.bmcl.2018.09.030. Epub 2018 Sep 24.

41.

Integrative Oncology Scholars Program: A Model for Integrative Oncology Education.

Zick SM, Czuhajewski C, Fouladbakhsh JM, Greenlee H, Harris RE, Henry NL, Jolly S, Khabir T, Perlmutter J, Remington T, Snyder D, Spratke L, Zebrack B, Zettell E, Benn R.

J Altern Complement Med. 2018 Sep/Oct;24(9-10):1018-1022. doi: 10.1089/acm.2018.0184.

42.

National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.

Seidman AD, Bordeleau L, Fehrenbacher L, Barlow WE, Perlmutter J, Rubinstein L, Wedam SB, Hershman DL, Hayes JF, Butler LP, Smith ML, Regan MM, Beaver JA, Amiri-Kordestani L, Rastogi P, Zujewski JA, Korde LA.

J Clin Oncol. 2018 Sep 13:JCO1800242. doi: 10.1200/JCO.18.00242. [Epub ahead of print]

PMID:
30212295
43.

ESM-CT: a precise method for localization of DBS electrodes in CT images.

Milchenko M, Snyder AZ, Campbell MC, Dowling JL, Rich KM, Brier LM, Perlmutter JS, Norris SA.

J Neurosci Methods. 2018 Oct 1;308:366-376. doi: 10.1016/j.jneumeth.2018.09.009. Epub 2018 Sep 7.

44.

Validation of diffusion tensor imaging measures of nigrostriatal neurons in macaques.

Shimony JS, Rutlin J, Karimi M, Tian L, Snyder AZ, Loftin SK, Norris SA, Perlmutter JS.

PLoS One. 2018 Sep 5;13(9):e0202201. doi: 10.1371/journal.pone.0202201. eCollection 2018.

45.

Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ; and I-SPY 2 Investigators.

NPJ Breast Cancer. 2018 Aug 17;4:26. doi: 10.1038/s41523-018-0074-6. eCollection 2018. Review. Erratum in: NPJ Breast Cancer. 2019 Jan 2;5:2.

46.

Mapping movement, mood, motivation and mentation in the subthalamic nucleus.

Gourisankar A, Eisenstein SA, Trapp NT, Koller JM, Campbell MC, Ushe M, Perlmutter JS, Hershey T, Black KJ.

R Soc Open Sci. 2018 Jul 18;5(7):171177. doi: 10.1098/rsos.171177. eCollection 2018 Jul.

47.

Selective D2 receptor PET in manganese-exposed workers.

Criswell SR, Warden MN, Searles Nielsen S, Perlmutter JS, Moerlein SM, Sheppard L, Lenox-Krug J, Checkoway H, Racette BA.

Neurology. 2018 Sep 11;91(11):e1022-e1030. doi: 10.1212/WNL.0000000000006163. Epub 2018 Aug 10.

48.

Exploration of Sulfur-Containing Analogues for Imaging Vesicular Acetylcholine Transporter in the Brain.

Luo Z, Liu H, Jin H, Gu J, Yu Y, Kaneshige K, Perlmutter JS, Parsons SM, Tu Z.

ChemMedChem. 2018 Sep 19;13(18):1978-1987. doi: 10.1002/cmdc.201800411. Epub 2018 Aug 19.

49.

Suicidal Ideation Assessment in Individuals with Premanifest and Manifest Huntington Disease.

Wesson M, Boileau NR, Perlmutter JS, Paulsen JS, Barton SK, McCormack MK, Carlozzi NE.

J Huntingtons Dis. 2018;7(3):239-249. doi: 10.3233/JHD-180299.

50.

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.

Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Kirshner JJ, Krop IE, Levinson J, Modi S, Patt DA, Perlmutter J, Winer EP, Lin NU.

J Clin Oncol. 2018 Sep 20;36(27):2804-2807. doi: 10.1200/JCO.2018.79.2713. Epub 2018 Jun 25.

PMID:
29939840

Supplemental Content

Loading ...
Support Center